Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?

Group 1: Company Performance - CorMedix (CRMD) has achieved a year-to-date performance increase of approximately 126.1%, significantly outperforming the average loss of 3.5% in the Medical sector [6] - ResMed (RMD) has also shown strong performance with a year-to-date return of 36% [6] - The Zacks Consensus Estimate for CRMD's full-year earnings has increased by 20.7% over the past three months, indicating a positive trend in analyst sentiment [5] Group 2: Industry Rankings - CorMedix is part of the Medical - Biomedical and Genetics industry, which consists of 501 individual stocks and currently ranks 61 in the Zacks Industry Rank [1] - The Medical - Products industry, which includes ResMed, has 87 stocks and is ranked 127 [1] - The Medical sector overall includes 1020 individual stocks and holds a Zacks Sector Rank of 2 [4]